Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune regulation and timing of cyclophosphamide chemotherapy in advanced/recurrent ovarian and endometrial cancer
2010-023457-11Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in ovarian cancer and endometrial cancer (EC), sponsored by UZ Leuven. Primary endpoint: Response rate (CA125 and RECIST). Started Jan 2011; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on 2010-023457-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023457-11.